Core Insights - SOPHiA GENETICS has launched SOPHiA DDM™ Digital Twins, a technology that creates virtual representations of individual patients to aid oncologists in treatment decision-making [1][7] - The Digital Twins utilize a patient's unique clinical, biological, imaging, and genomic data to simulate treatment responses and disease trajectories in real time [1][4] - This technology aims to enhance personalized treatment insights, reduce unnecessary side effects and costs, and leverage a global dataset for improved clinical decisions [6][7] Technology Overview - SOPHiA DDM™ Digital Twins enables integrative visualization of multimodal oncologic data, revealing correlations across different data types [2] - The technology supports in silico experimentation, allowing for anticipatory and individualized clinical decision-making [2][4] - It continuously evolves with new data, improving accuracy and research capabilities over time [5][6] Clinical Implications - The Digital Twins concept is seen as transformative for oncology, particularly in managing complex cancers and pre-surgical immunotherapy for non-small cell lung cancer [3][5] - Clinicians can simulate potential outcomes before treatment, which may significantly change future care delivery [3][4] - The tool provides insights derived from a broad network of global patient cases, breaking down institutional and geographic barriers [3][6] Future Directions - The launch of Digital Twins marks a shift towards AI-powered decision support in precision oncology, moving beyond retrospective evidence [7] - Initially available for lung cancer, the technology will expand to include more cancer types in the coming months [7] - SOPHiA GENETICS aims to make data-driven medicine the global standard of care through this innovative approach [6]